Page last updated: 2024-11-06

niaprazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Niaprazine is a non-selective, irreversible inhibitor of monoamine oxidase (MAO) and was initially investigated as a potential antidepressant. Its mechanism of action involves the inhibition of MAO, an enzyme responsible for breaking down neurotransmitters like serotonin, norepinephrine, and dopamine in the brain. However, niaprazine exhibited significant hepatotoxicity in clinical trials and was withdrawn from development due to safety concerns. Studies on niaprazine have focused on its pharmacological properties, potential therapeutic applications, and its interaction with MAO. Research into niaprazine, despite its discontinuation as an antidepressant, offers valuable insights into the role of MAO inhibition in neurotransmission and the challenges associated with developing drugs targeting this enzyme.'

niaprazine: selective brain catecholamine depletor; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71919
CHEMBL ID2105141
CHEBI ID135505
SCHEMBL ID352977
MeSH IDM0075521

Synonyms (54)

Synonym
niaprazine [inn:dcf]
n-(3-(4-(p-fluorophenyl)-1-piperazinyl)-1-methylpropyl)nicotinamide
nopron
nicotinamide, n-(3-(4-(p-fluorophenyl)-1-piperazinyl)-1-methylpropyl)-
1709 cerm
brn 0844157
3-pyridinecarboxamide, n-(3-(4-(4-fluorophenyl)-1-piperazinyl)-1-methylpropyl)-
einecs 248-431-5
niaprazine
n-(3-(4-(4-fluorophenyl)-1-piperazinyl)-1-methylpropyl)-3-pyridinecarboxamide
niaprazina [inn-spanish]
niaprazinum [inn-latin]
27367-90-4
nopron (tn)
niaprazine (inn)
D07333
CHEBI:135505
n-[4-[4-(4-fluorophenyl)piperazin-1-yl]butan-2-yl]pyridine-3-carboxamide
1709-cerm
CHEMBL2105141
1709cerm
j10.716f ,
niaprazina
unii-r2h3yn6e3l
niaprazinum
r2h3yn6e3l ,
FT-0687290
niaprazine [mart.]
niaprazine [who-dd]
niaprazine [mi]
niaprazine [inn]
SCHEMBL352977
AKOS022185020
3-pyridinecarboxamide, n-(3-(4-(4-fluorophenyl)-1-piperazinyl)-1-methylpropyl)-, (+)-
niaprazine, (-)-
5QKW305N9F ,
niaprazine, (+)-
1346Q758L9 ,
3-pyridinecarboxamide, n-(3-(4-(4-fluorophenyl)-1-piperazinyl)-1-methylpropyl)-, (-)-
119306-37-5
119328-74-4
unii-5qkw305n9f
unii-1346q758l9
Q631457
n-(4-(4-(4-fluorophenyl)piperazin-1-yl)butan-2-yl)nicotinamide
E75895
DB13687
1709cerm; nopron
BS-49185
HY-105542
n-{4-[4-(4-fluorophenyl)piperazin-1-yl]butan-2-yl}pyridine-3-carboxamide
DTXSID10865369
CS-0026220
AC-36434

Research Excerpts

Overview

Niaprazine is a histamine H1-receptor antagonist with marked sedative properties.

ExcerptReferenceRelevance
"Niaprazine is a histamine H1-receptor antagonist with marked sedative properties. "( Niaprazine in the treatment of autistic disorder.
D'Agata, M; Parmeggiani, A; Pipitone, E; Posar, A; Rossi, PG, 1999
)
3.19

Dosage Studied

ExcerptRelevanceReference
" Niaprazine at a daily dosage of 1 mg/kg body weight or placebo at random was administered to a selected group of 36 children (aged from 6 months to 6 years) suffering from frequent nighttime waking or inability to fall asleep."( The effect of niaprazine on some common sleep disorders in children. A double-blind clinical trial by means of continuous home-videorecorded sleep.
Cortesi, F; Giannotti, F; Ottaviano, S, 1991
)
1.55
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (45.45)18.7374
1990's4 (36.36)18.2507
2000's0 (0.00)29.6817
2010's2 (18.18)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.76 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index44.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (26.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies6 (40.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (33.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]